Biotech start-ups may adopt different business models, either focusing on developing specific assets or leveraging technology platforms to address multiple indications. What are the key differences between asset-based and technology platform-based start-ups, and how do they impact investors’ perceptions and preferences? What are the advantages and challenges of each business model from an investment perspective, and how can entrepreneurs effectively communicate their value proposition to investors? How do funding mechanisms vary and what implications do they have for entrepreneurs?
Moderator: Ester Caffarel-Salvador, Director, Strategic Innovation, Rare Diseases, Chiesi USA 
